These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 22507415)

  • 21. Recent improvements in the detection and treatment of nonmuscle-invasive bladder cancer.
    Kausch I; Doehn C; Jocham D
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1301-11. PubMed ID: 17020462
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of statin use with improved local control in patients treated with selective bladder preservation for muscle-invasive bladder cancer.
    Tsai HK; Katz MS; Coen JJ; Zietman AL; Kaufman DS; Shipley WU
    Urology; 2006 Dec; 68(6):1188-92. PubMed ID: 17141846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.
    Sawczuk IS; Bagiella E; Sawczuk AT; Yun EJ
    Cancer Detect Prev; 2000; 24(4):364-8. PubMed ID: 11059567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ta T1 low and intermediate transitional cell carcinoma of the bladder: recurrence rates and the timing of check cystoscopies within the first year.
    Guney S; Guney N; Canogullari Z; Ergenekon E
    Urol Int; 2008; 80(2):124-8. PubMed ID: 18362479
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) members.
    Matulay JT; Tabayoyong W; Duplisea JJ; Chang C; Daneshmand S; Gore JL; Holzbeierlein JM; Karsh LI; Kim SP; Konety BR; Li R; McKiernan JM; Messing EM; Steinberg GD; Williams SB; Kamat AM
    Urol Oncol; 2020 Oct; 38(10):796.e1-796.e6. PubMed ID: 32430255
    [TBL] [Abstract][Full Text] [Related]  

  • 27. General adherence to guideline recommendations on initial diagnosis of bladder cancer in the United States and influencing factors.
    Karl A; Adejoro O; Saigal C; Konety B;
    Clin Genitourin Cancer; 2014 Aug; 12(4):270-7. PubMed ID: 24332507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base.
    David KA; Milowsky MI; Ritchey J; Carroll PR; Nanus DM
    J Urol; 2007 Aug; 178(2):451-4. PubMed ID: 17561135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current strategies for first and second line intravesical therapy for nonmuscle invasive bladder cancer.
    Hendricksen K; Witjes JA
    Curr Opin Urol; 2007 Sep; 17(5):352-7. PubMed ID: 17762630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The value of the UroVysion assay for surveillance of non-muscle-invasive bladder cancer.
    Gudjónsson S; Isfoss BL; Hansson K; Domanski AM; Warenholt J; Soller W; Lundberg LM; Liedberg F; Grabe M; Månsson W
    Eur Urol; 2008 Aug; 54(2):402-8. PubMed ID: 18082934
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study.
    Gudjónsson S; Adell L; Merdasa F; Olsson R; Larsson B; Davidsson T; Richthoff J; Hagberg G; Grabe M; Bendahl PO; Månsson W; Liedberg F
    Eur Urol; 2009 Apr; 55(4):773-80. PubMed ID: 19153001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Postoperative and adjuvant intravesical therapy of superficial bladder tumours. Clinical practice and applied therapeutic agents].
    Lingnau A; Miller K; Steiner U; Jentzmik F; Weikert S; Schostak M
    Aktuelle Urol; 2009 Sep; 40(5):307-9. PubMed ID: 19637135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk of concomitant carcinoma in situ determining biopsy candidates among primary non-muscle-invasive bladder cancer patients: retrospective analysis of 173 Japanese cases.
    Hara T; Takahashi M; Gondo T; Nagao K; Ohmi C; Sakano S; Naito K; Matsuyama H
    Int J Urol; 2009 Mar; 16(3):293-8. PubMed ID: 19207607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Urine markers for detection and surveillance of non-muscle-invasive bladder cancer.
    Tilki D; Burger M; Dalbagni G; Grossman HB; Hakenberg OW; Palou J; Reich O; Rouprêt M; Shariat SF; Zlotta AR
    Eur Urol; 2011 Sep; 60(3):484-92. PubMed ID: 21684071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of superficial bladder cancer in Victoria: 1990 and 1995.
    Frydenberg M; Millar JL; Toner G; Bolton D; Syme R; Thursfield VJ; Giles GG;
    ANZ J Surg; 2005 May; 75(5):270-4. PubMed ID: 15932435
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identifying better practices for early-stage bladder cancer.
    Hollingsworth JM; Zhang YS; Miller DC; Skolarus TA; Wood DP; Lee CT; Montie JE; Hollenbeck BK
    Med Care; 2011 Dec; 49(12):1112-7. PubMed ID: 21979371
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can the burden of follow-up in low-grade noninvasive bladder cancer be reduced by photodynamic diagnosis, perioperative instillations, imaging, and urine markers?
    Gakis G; Kruck S; Stenzl A
    Curr Opin Urol; 2010 Sep; 20(5):388-92. PubMed ID: 20657287
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
    Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-invasive bladder cancer.
    Serretta V; Morgia G; Altieri V; Di Lallo A; Ruggiero G; Salzano L; Battaglia M; Falsaperla M; Zito A; Sblendorio D; Melloni D; Allegro R;
    BJU Int; 2010 Jul; 106(2):212-7. PubMed ID: 20070299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic impact of tumor markers in bladder cancer surveillance.
    Hong YM; Loughlin KR
    Urology; 2008 Jan; 71(1):131-5. PubMed ID: 18242381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.